PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer
暂无分享,去创建一个
T. Fujiwara | T. Nagasaka | S. Kagawa | H. Tazawa | Nobuhiko Kanaya | Shinji Kuroda | Satoru Kikuchi | Takehiro Tanaka | T. Kubota | M. Nishizaki | Yoshihiko Kakiuchi | Katsuyuki Aoyama | Toshiaki Morihiro | Takehiro Tanaka
[1] J. Machan,et al. Expression of PD‐L1, indoleamine 2,3‐dioxygenase and the immune microenvironment in gastric adenocarcinoma , 2018, Histopathology.
[2] T. Fujiwara,et al. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors , 2018, Journal of Translational Medicine.
[3] T. Yoshikawa,et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[4] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[5] P. Keegan,et al. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.
[6] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[7] Xinlong Li,et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis , 2017, PloS one.
[8] H. Bae,et al. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology , 2017, World journal of gastrointestinal oncology.
[9] Qi Zhou,et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis , 2017, Oncotarget.
[10] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[11] Su Jin Heo,et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.
[12] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[13] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[14] Steven J. M. Jones,et al. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer , 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[15] Xiaoshan Feng,et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis , 2016, OncoTargets and therapy.
[16] M. Shimada,et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection , 2016, Gastric Cancer.
[17] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] K. Hirakawa,et al. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. , 2015, Anticancer research.
[19] Jian Huang,et al. PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.
[20] Matteo Brunelli,et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.
[21] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[22] Yan Wang,et al. Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. , 2015, Molecular and clinical oncology.
[23] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[24] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[25] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[26] M. Gulley. Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma , 2015, Experimental & Molecular Medicine.
[27] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[28] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[29] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[30] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[31] K. Bickenbach,et al. Comparisons of Gastric Cancer Treatments: East vs. West , 2012, Journal of gastric cancer.
[32] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[33] C. Boland,et al. An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers , 2010, PloS one.
[34] F. Schmidt. Meta-Analysis , 2008 .
[35] D. Kennedy. Breakthrough of the Year , 2004, Science.
[36] O. Dogar. in with a randomised, double-blind, placebo-controlled phase 3 trial , 2021 .
[37] Sang-Hoon Ahn,et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer , 2014, Gastric Cancer.
[38] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.
[39] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[40] A. Jemal,et al. Global Cancer Statistics , 2011 .